LDLR and familial hypercholesterolemia: A more recent preclinical study applied CRISPR/Cas9 system delivered by AAV to realize gene editing of Ldlr in mutant knock-in mouse model, and determined in vivo AAV-CRISPR/Cas9 somatic cell gene editing could correct LDLR mutations and ameliorate hypercholesterolemia.